WSJ What’s News – Episode: "Chinese Biotech Is Having A DeepSeek Moment"
Release Date: February 7, 2025
Host: Alex Osola
Produced by: Anthony Bansi

U.S. January Jobs Report Overview

Timestamp [01:00]
Host Alex Osola opens the episode by discussing the latest U.S. labor market data. The Labor Department reported that the economy added 143,000 jobs in January, slightly below economists’ expectations of 169,000 jobs. Concurrently, the unemployment rate decreased to 4%, also surpassing forecasts.

Timestamp [01:47]
David Wehner, WSJ Finance News Editor, provides insight into the seemingly conflicting figures. He explains, “The job market has been doing well. This isn't like 2021, when the economy was reopening. I wouldn't say that we're in a slow period for the jobs market, but we are maybe normalizing a bit more.” Wehner highlights that while job creation has slowed compared to previous months, the unemployment rate's decline indicates underlying strength in the labor market.

Timestamp [02:40]
Wehner further elaborates on the sectors contributing to job growth, noting that retail, government, and healthcare were primary contributors. However, he points out a slowdown in leisure, hospitality, and construction, areas that traditionally drive substantial employment.

Timestamp [03:30]
Discussing future implications, Wehner addresses the potential impact of former President Trump’s policies on employment. He cautions, “Economists tend to think that tariffs are bad for the jobs market because it hurts companies that depend on imports and exports.” Additionally, he mentions that changes in immigration policies could significantly affect the labor market by limiting growth if mass deportations occur.

Market Reactions and Consumer Sentiment

Timestamp [04:50]
The episode transitions to the stock market's response to the mixed jobs report. Alex notes that major indexes like the Dow and S&P 500 dipped approximately 1%, while the Nasdaq fell around 1.4%.

A University of Michigan survey revealed a 5% decline in consumer sentiment in February, the lowest since July of the previous year. Factors contributing to this pessimism include tariff threats, stock market volatility, and rapidly changing executive orders, which have raised concerns about the U.S. economic outlook.

Chinese Biotech's Ascendancy in Pharma

Timestamp [06:26]
The core focus of the episode shifts to the burgeoning Chinese biotechnology sector. Alex introduces the topic, stating, “China's biotech industry has been looking to do the same in pharma. And their moment may be here in 2020.” Citing data from Deal Phorma, he notes a significant increase in large pharmaceutical transactions involving China, from less than 5% to nearly 30% within a year.

Timestamp [07:05]
Christina Rexrode joins the discussion, outlining the factors propelling China’s biotech rise:

• Talent Repatriation: “Many of the top scientists that have trained in the US over recent decades have returned to China, and that's fueling the emergence of a biotech hub, particularly around Shanghai.” The return of skilled professionals has been pivotal in establishing robust research and development capabilities within China.

• Cost Efficiency: Christina emphasizes the cost advantages Chinese biotech companies possess. “Chinese biotech companies are a lot scrappier. They can work with really highly skilled chemists and pay them a fraction of what you would typically pay someone of that level here in the US.” This cost-effectiveness allows for more extensive and affordable research initiatives.

• Streamlined Processes: The Chinese government has actively streamlined approval and clinical trial processes, enabling faster and more cost-effective drug development. “They've streamlined the approval process and the clinical trial process, like what it takes to get a study off the ground, what it takes to get a drug approved, that sort of thing.”

Timestamp [08:00]
Alex probes into the types of treatments being developed, with Christina responding, “It's really anywhere from your cutting edge cancer medication to obesity pill.” While China is advancing in various therapeutic areas, Christina clarifies that much of the innovation builds upon existing U.S. research rather than introducing entirely new scientific modalities.

Timestamp [08:46]
Addressing the perspective of Western pharmaceutical companies, Christina notes varying strategies based on company size. “If you're a big, big pharma company, this might be a very good opportunity for you because you might think, why should I pay $10 billion to acquire a startup or a mid-sized company developing a couple of medications in the US or Europe when I could potentially look in China and pay a fraction of the cost?” Large companies may find strategic acquisitions in China more financially viable, while biotech firms must navigate data privacy and regulatory landscapes effectively.

Additional News Highlights

• Nippon Steel Investment Deal: President Trump expressed support for a restructured agreement allowing Japanese steel company Nippon Steel to invest in U.S. Steel without full ownership, reversing the Biden administration’s prior blockage of a $14 billion takeover [Timestamp not specified].

• Aviation Incidents: Alaska authorities are searching for a missing commercial plane over the Bering Sea, marking the third major U.S. aviation incident in ten days. This follows prior crashes involving an American Airlines jet and a medical transport jet, heightening public concern over aviation safety [Timestamp not specified].

• Travel Tips from Dawn Gilbertson: Columnist Dawn Gilbertson shares her experience of securing a last-minute cruise spot by going on standby, offering advice on maximizing value and ensuring availability [Timestamp [11:23]-[11:59]].

Upcoming Segments and Closing Remarks

Alex Osola previews upcoming content, including:

• Bonus Episode: An analysis of major insurance companies’ strategies in response to extreme weather events like the Los Angeles wildfires and their impact on insurance costs.

• Weekly Markets Wrap-Up: Scheduled for the following day.

• What’s News Sunday: A deep dive into geopolitical dynamics in the Arctic, focusing on President Trump's interest in Greenland.

The episode concludes with acknowledgments of the production team, highlighting contributions from Anthony Bansi, Michael Kosmides, Michael Lavalle, Aisha El Musleam, Scott Salloway, Chris Insinsley, and Valona Patterson.

Notable Quotes:

• David Wehner [01:47]: “The job market has been doing well. This isn't like 2021, when the economy was reopening. I wouldn't say that we're in a slow period for the jobs market, but we are maybe normalizing a bit more.”

• Christina Rexrode [07:05]: “Many of the top scientists that have trained in the US over recent decades have returned to China, and that's fueling the emergence of a biotech hub, particularly around Shanghai.”

• Christina Rexrode [08:46]: “If you're a big, big pharma company, this might be a very good opportunity for you because you might think, why should I pay $10 billion to acquire a startup or a mid-sized company developing a couple of medications in the US or Europe when I could potentially look in China and pay a fraction of the cost?”

This comprehensive summary encapsulates the episode's key discussions, providing valuable insights into the U.S. labor market, market reactions, and the strategic growth of China's biotechnology sector, all while highlighting pertinent quotes and maintaining a clear, structured flow for listeners and readers alike.